Purple Biotech (PPBT) Other Accumulated Expenses (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Other Accumulated Expenses data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 24.37% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 24.37% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 14.42% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.7 million, up from $1.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PPBT reached as high as $5.3 million in Q1 2022 and fell as low as $1.2 million in Q2 2025.
• Historically, Other Accumulated Expenses has averaged $2.6 million across 5 years, with a median of $2.8 million in 2024.
• Across the five-year window, Other Accumulated Expenses surged 223.72% in 2022 and sank 65.35% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $4.7 million in 2022, then declined by 26.82% to $3.5 million in 2023, then sank by 65.35% to $1.2 million in 2024, then advanced by 14.42% to $1.4 million in 2025, then increased by 21.56% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.7 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.